A23V2250/2131

METHODS AND COMPOSITIONS FOR REDUCING DAMAGE ASSOCIATED WITH OXIDATIVE PHOSPHORYLATION
20180008573 · 2018-01-11 ·

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

METHODS AND COMPOSITIONS FOR REDUCING DAMAGE ASSOCIATED WITH OXIDATIVE PHOSPHORYLATION
20180008573 · 2018-01-11 ·

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

Biomediated-titanium nanocomposite for corrosion protection

The present invention relates to a method of inhibiting corrosion of steel in contact with a corrosive solution. The method involves mixing an olive leaf extract titanium nanocomposite with the corrosive solution. The olive leaf extract titanium nanocomposite may be made by reducing TiCl.sub.4 with an olive leaf extract, which forms nanoparticles with an average size of 50-100 nm.

Glutamic Acid Containing Gluten-Free Dough
20170347671 · 2017-12-07 ·

A packaged refrigerated gluten-free dough composition comprises at least one gluten-free flour source in at least 35% by weight of the composition, at least one starch source in at least 2% by weight of the composition and at least one protein source in about 0.5% to 13% by weight of the composition and at least 17 grams of glutamic acid per 100 grams of the protein, at least one fat source from 4% to 10% by weight of the composition and water from 25% to 35% by weight of the composition. The dough has an average storage modulus ranging from about 45 kPa to about 60 kPa at about 40° F. and an average loss modulus ranging from about 10 kPa to about 20 kPa at about 40° F. after at least 24 hours of storage at about 40° F., and is substantially free of gluten protein.

PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES

The present invention relates to cancer therapy by administering a specific dietary compensation. Especially the invention relates to a pharmaceutical, medical food or dietary supplement composition comprising the combination of the following three active ingredients: hydroxytyrosol, fish oil EPA/DHA and curcumin. The pharmaceutical composition is useful in the treatment or prevention of cancer, especially breast cancer.

PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES

The present invention relates to cancer therapy by administering a specific dietary compensation. Especially the invention relates to a pharmaceutical, medical food or dietary supplement composition comprising the combination of the following three active ingredients: hydroxytyrosol, fish oil EPA/DHA and curcumin. The pharmaceutical composition is useful in the treatment or prevention of cancer, especially breast cancer.

COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF
20220265705 · 2022-08-25 ·

A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to decrease muscle fatigue in an individual who participates in at least one of 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise. Preferably, the combination of calcium and at least one of oleuropein or metabolite thereof is administered to the individual less than two hours before the exercise, and/or during the exercise, and/or less than two hours after the exercise.

COMPOSITIONS AND METHODS USING AT LEAST ONE OF OLEUROPEIN OR A METABOLITE THEREOF TO TREAT OR PREVENT MUSCLE FATIGUE FROM EXERCISE AND/OR FOR RESISTANCE TO MUSCLE FATIGUE FROM EXERCISE

A method of preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including orally administering at least one of oleuropein or metabolite thereof to an individual before, during and/or after the exercise. A unit dosage form contains at least one of oleuropein or metabolite thereof in an amount effective for administration of the unit dosage form before, during and/or after exercise to thereby prevent or treat muscle fatigue from the exercise and/or for resistance to muscle fatigue from exercise. A method of making a composition for preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including adding an effective amount of at least one of oleuropein or metabolite thereof to at least one ingredient selected from the group consisting of protein, carbohydrate, and fat. The exercise is preferably one or more of 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise.

COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF
20220211750 · 2022-07-07 ·

A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells, (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and/or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.

COMPOSITIONS AND METHODS USING AT LEAST ONE OF OLEUROPEIN OR A METABOLITE THEREOF TO TREAT OR PREVENT MUSCLE FATIGUE FROM EXERCISE AND/OR FOR RESISTANCE TO MUSCLE FATIGUE FROM EXERCISE
20220256888 · 2022-08-18 ·

A method of preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including orally administering at least one of oleuropein or metabolite thereof to an individual before, during and/or after the exercise. A unit dosage form contains at least one of oleuropein or metabolite thereof in an amount effective for administration of the unit dosage form before, during and/or after exercise to thereby prevent or treat muscle fatigue from the exercise and/or for resistance to muscle fatigue from exercise. A method of making a composition for preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including adding an effective amount of at least one of oleuropein or metabolite thereof to at least one ingredient selected from the group consisting of protein, carbohydrate, and fat. The exercise is preferably one or more of 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise.